United States
Firm says its work with a biotech client could signal a sea change in how - and when - law firms enter the drug development process
Evan Lazerowitz, attorney in Robinson + Cole’s bankruptcy and reorganisation group, offers key takeaways for IP interested parties in bankruptcy and insolvency proceedings
With drug prices a hot topic in the US, courts are seemingly more reluctant to prevent the entry of generics to the market
Academic Eden Sarid joins us during Pride Month to discuss queer expression and IP law, Patagonia v Pattie Gonia, and how queer and AI-generated creations both pose novelty concerns
Sponsored
Sponsored
-
Sponsored by Bird & BirdAnne-Raphaëlle Aubry of Bird & Bird explains how Section 1782 and Rule of Procedure 190 offer different pathways for cross-border evidence gathering in European patent disputes, highlighting timing, scope, and strategic considerations for litigants -
Sponsored by CASPatent rejections are common, but avoidable, setbacks. This CAS article explores how comprehensive intellectual property insights, expert searches, and proactive strategies can help innovators anticipate rejections and secure stronger patent applications
-
Sponsored by CASKathy Van der Herten and Don Swartwout of CAS discuss the benefits and challenges of using emerging technologies to help with IP searches
-
Sponsored by Ropes & GrayLawyers from Ropes & Gray joined Managing IP to discuss licensing negotiation groups
-
Sponsored by CASPatent landscape analysis helps R&D teams identify trends, optimise resources, and seize innovation opportunities. This article, originally published by CAS, explains how to leverage the right tools to stay ahead of the competition
-
Sponsored by CASMatt Garver and Peter Mattei of CAS explain what information companies should be getting from patent monitoring programmes
